April 06, 2022
Video
Study co-chair Paul Ridker, MD, shares details behind the new global assessment of the IL-6 inhibitor for patients with atherosclerosis and CKD.
April 05, 2022
Article
National registry data suggest management and outcomes of ST-elevation myocardial infarction are returning to pre-pandemic levels, though vaccinated patients have fared better in mortality.
April 04, 2022
Data from PROMPT-HF show clinicians are more likely to add 1 of 4 topline drug classes to a patient's HFrEF regimen when alerted on the opportunity.
Data show omecamtiv mecarbil added to background therapy had no significant improvement regarding exercise capacity.
Mikhail Kosiborod, MD, discusses EMPULSE findings supporting hospital-stage treatment with the SGLT-2—regardless of patients' diabetes status.
Peter Sogaard discusses the benefit of monitoring for arrhythmias in patients with non-STEMI heart attacks and the need to look at arrhythmias in a different light.
Paul M. Ridker, MD, discusses the latest findings from the canakinumab trial before highlighting his team's work with ziltevekimab in ZEUS.
Dr. Butler discusses findings from the FIDELITY analyses on the consistent benefits of finerenone, regardless of ASCVD history in patients with CKD and T2D.
A discussion into broadening the findings of the SuperWIN trial and its potential effects on a larger, more at-risk population.
Study author Deepak L. Bhatt, MD, MPH, discusses the unique SGLT-1 and SGLT-2 inhibition derived from sotagliflozin, and how impactful its benefit may be.
Carolyn Rowley, PhD, Addresses Mental Health and Wellness in People with Sickle Cell Disease
David Au, MD, MS: Lifestyle Interventions for Weight Loss in Obese Patients with COPD
Claims-Based Algorithm Identifies PAH 6 Months Prior to Diagnosis
